---
title: "JUNSHI BIO Opens 11.11% Higher After Signing Licensing Agreement with Fosun Wanbang"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291482147.md"
description: "JUNSHI BIOshares surged over 11% after announcing a licensing agreement with Fosun Wanbang, a subsidiary of FOSUN PHARMA. Under the deal, JUNSHI BIO grants rights to develop and commercialize its anti-IL-17A monoclonal antibody, roconkibart, in Greater China. The company will receive an upfront payment of RMB215 million, potential milestone payments up to RMB1.125 billion, and double-digit tiered royalties on net sales."
datetime: "2026-07-02T01:50:39.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291482147.md)
  - [en](https://longbridge.com/en/news/291482147.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291482147.md)
generator: "portal-rs"
---

# JUNSHI BIO Opens 11.11% Higher After Signing Licensing Agreement with Fosun Wanbang

JUNSHI BIO (01877.HK) +2.200 (+13.213%) Short selling $17.69M; Ratio 15.594% opened 11.11% higher today at HKD18.5, with 90,400 shares traded pre-market, involving HKD1.6724 million.

JUNSHI BIO announced that on 30 June 2026, the Company entered into a license agreement with Fosun Wanbang, a wholly-owned subsidiary of FOSUN PHARMA (02196.HK) +0.890 (+5.890%) Short selling $7.09M; Ratio 7.182% . Pursuant to the License Agreement, the Company will grant Fosun Wanbang the right to develop, register, manufacture and commercialize roconkibart ("JS005" or "anti-IL-17A monoclonal antibody") in the Greater China region (including the Chinese mainland, Hong Kong Special Administrative Region, Macao Special Administrative Region, and Taiwan region). 

Under the License Agreement, the Company will receive an upfront payment of RMB215 million (tax inclusive), which shall be non-deductible and non-refundable, and will be eligible to receive milestone payments for product development and sales of RMB1.125 billion (tax inclusive), as well as double-digit tiered royalties based on net sales in the Greater China region.  
(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-06-30 16:25.)

### Related Stocks

- [01877.HK](https://longbridge.com/en/quote/01877.HK.md)
- [688180.CN](https://longbridge.com/en/quote/688180.CN.md)
- [02196.HK](https://longbridge.com/en/quote/02196.HK.md)
- [600196.CN](https://longbridge.com/en/quote/600196.CN.md)

## Related News & Research

- [Fosun Pharma unit starts China Phase II trial of COPD drug candidate FXS7553](https://longbridge.com/en/news/295775012.md)
- [Fosun Pharma Sets March 2026 Board Meeting to Approve 2025 Results and Dividend Plan](https://longbridge.com/en/news/278366476.md)
- [Junshi Biosciences Enters Licensing Collaboration with Fosun Wanbang on Roconkibart (IL-17A)](https://longbridge.com/en/news/291476385.md)
- [Junshi Biosciences Shareholders Approve H-Share Buyback Mandate](https://longbridge.com/en/news/293923779.md)
- [Junshi Biosciences Wins NMPA Nod to Expand Toripalimab Use in Early-Stage Lung Cancer](https://longbridge.com/en/news/293373812.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**